Koers Curis, Inc. Nasdaq
Aandelen
US2312691015
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 8,61 mln. 8,07 mln. | Omzet 2025 * | 8,96 mln. 8,4 mln. | Marktkapitalisatie | 86,7 mln. 81,28 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -49 mln. -45,93 mln. | Nettowinst (verlies) 2025 * | -54 mln. -50,62 mln. | EV/omzet 2024 * | 10,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 9,67 x |
K/w-verhouding 2024 * |
-2,37
x | K/w-verhouding 2025 * |
-2,86
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,82% |
Recentste transcriptie over Curis, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29-03-16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26-07-22 |
Chief Tech/Sci/R&D Officer | - | 03-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 01-11-03 | |
Chairman | 82 | 14-02-00 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 29-03-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |